OsNovum

04/14/2026

OsNovum Is Closing Soon. This is the last opportunity to invest. We have completed our testing and are ready to submit to the FDA.

04/03/2026

In process for FDA submission.

03/16/2026

https://www.linkedin.com/feed/update/urn:li:activity:7439403068267589632

We are ready to submit to the FDA. Please help us reach our goal before April. Shares are still at $40 but this will not be the case after FDA clearance.

03/11/2026

Investors - OsNovum is ready for FDA submission. Please help us raise the needed funds to help the osteoportic community.

Oversubscribed and gaining speed.

We hit our $124,000 cap, raised over $50,000 in just a few days, and we’re not slowing down.

Our next milestone: $1.235M. Let’s build the future of bone regeneration together:

Invest today: www.wefunder.com/osnovum

04/30/2025

Oversubscribed and gaining speed.

We hit our $124,000 cap, raised over $50,000 in just a few days, and we’re not slowing down.

Our next milestone: $1.235M. Let’s build the future of bone regeneration together:

Invest today: www.wefunder.com/osnovum

04/14/2025

📈 $34,600 in the last 4 days. 😳
When we quietly kicked off our final stretch campaign last week, we didn’t expect this kind of momentum. But in the past 100 hours, you’ve all shown up in a huge way.

As of this post, we’re just $2,968 away from hitting our Wefunder campaign cap. That’s $124,000 raised from people who believe in this mission and see what we see:
🔹 A future where patients don’t have to choose between bone fractures and brutal side effects.
🔹 A future where innovation in bone health finally catches up to the people it’s supposed to serve.
🔹 A future of skeletal health we’re building brick by brick, voice by voice, bone by bone.

We don’t take a single dollar or ounce of trust for granted. Every investment brings us closer to FDA submission. Time is the only thing we can’t rush, but thanks to this community, we can stay patient and stay ready.

If you’re one of the many who helped us get here: thank you.

If you’re one of the few who want to help close the gap: now’s the time.

And if you’re someone who sees an opportunity to help—from clinicians to journalists to caretakers—know this: we’d love to hear from you.

This isn’t the end. It’s just the part where things start to move.
🔗 www.wefunder.com/osnovum

04/09/2025

Greetings from the OsNovum Team,
A lot has happened since we last reached out. Our regenerative bone graft technology is now approaching a pivotal moment: we’re in the final stages before FDA submission. After a productive pre-submission consultation with Bruder Consulting, we’ve confirmed that a De Novo submission (which skips human clinical trials) is the most efficient pathway to market. We’ve got the science, the partners, the strategy—and now we need one final push. Thanks to our lean structure and support from SteinerBio, we’ve made it this far with minimal cash burn. We don’t pay staff, rent, or equipment costs. Our testing is complete. What’s left is the final step: submission and clearance. We’re officially 3 weeks away from the close of our Wefunder campaign—and just $30,000 short of what we need to ensure a smooth FDA clearance. That’s $10K per week for the next 3 weeks. And that’s where you come in. This is the critical stretch. Every investment now, whether $100 or $1,000, directly supports our FDA strategy and accelerates our launch. And this isn’t speculative: our product is based on real success in the dental industry, with over 15 years of safe, documented performance. We’ve already raised $301,454 from 219 investors who believe in what we’re building. Now, we’re asking you to join them. If you’ve been following our journey—or if you’re just now hearing the urgency—we hope you’ll consider jumping in. The timing couldn’t be more important. The finish line is in sight. Let’s cross it together and visit osnovum.com to invest.
With sincere thanks,
Roslynn Steiner
CEO, OsNovum

04/07/2025

A recent study found that women’s choices about osteoporosis medications don’t align with the thresholds doctors use to recommend treatment.

On paper, it might look like “non-adherence.”

But what if it’s actually something deeper?

What if these decisions reflect a thoughtful—and sometimes skeptical—approach to risk, aging, and identity?

At OsNovum, we don’t believe people are “non-compliant.” We believe they’re navigating a complicated landscape with the information, experiences, and emotions they have.

And when their decisions surprise us, that’s not a failure of education. It’s an invitation to listen more closely.

Read the full article:
https://pmc.ncbi.nlm.nih.gov/articles/PMC6957614/

03/13/2025

They trusted the system. They system is letting them down.

Millions of women with osteoporosis face an impossible choice: endure painful fractures or suffer from the harsh side effects of current medications. They deserve better. We all deserve better.

At OsNovum, we’re not just imagining a future where bone health is redefined—we’re building it. This is more than innovation; it’s a movement. And you have the power to be part of it.

💡 Watch this video. Feel the urgency. See the change.

💰 Invest in OsNovum today and help bring a breakthrough treatment to millions.

🔗 www.wefunder.com/osnovum